Inventiva raises €48 million in a successful initial public offering
Announces initiation of Phase IIb Clinical Trial of IVA337 in NASH
IVA337 delivers significant therapeutic advances
in fibrosis, a major public health challenge
Developing breakthrough therapies in rare diseases
DEVELOPING BREAKTHROUGH THERAPIES IN RARE DISEASES
No front page content has been created yet.